Estrella Immunopharma, Inc. (NASDAQ: ESLA; ESLAW) Receives Buy Rating with a 12-Month Price Target of $16.00 from D. Boral Capital

9 months ago 39
Read Entire Article
  1. Homepage
  2. Finance
  3. Estrella Immunopharma, Inc. (NASDAQ: ESLA; ESLAW) Receives Buy Rating with a 12-Month Price Target of $16.00 from D. Boral Capital

Related

Wild currency swings put emerging markets in the spotlight

Wild currency swings put emerging markets in the spotlight

26 minutes ago 0
Citizens initiates Spotify stock coverage with Market Outperform rating

Citizens initiates Spotify stock coverage with Market Outper...

26 minutes ago 0
TotalEnergies sells 50% stake in Greek renewable assets to Asterion

TotalEnergies sells 50% stake in Greek renewable assets to A...

26 minutes ago 0

Trending

1. pge
2. puget sound energy
3. power outage near me
4. covid symptoms
5. portland weather
6. flood warning
7. heath ledger
8. steve harvey
9. bbl
10. toys

Popular

College football by the odds: Vegas picks and preview of Ohio State vs. Notre Dame

College football by the odds: Vegas picks and preview of Ohi...

10 months ago 634
What is Tren de Aragua, the Venezuelan gang targeted by Trump?

What is Tren de Aragua, the Venezuelan gang targeted by Trum...

9 months ago 501
Taiwan slightly cuts 2025 GDP growth outlook amid Trump tariffs concern

Taiwan slightly cuts 2025 GDP growth outlook amid Trump tari...

9 months ago 369
Australian whose blood saved 2.4 million babies dies

Australian whose blood saved 2.4 million babies dies

9 months ago 325
What to do in Las Vegas this week: January 2-8

What to do in Las Vegas this week: January 2-8

11 months ago 321
English (US) English (US) ·
About Us · Contact Us · Terms & Conditions ·

© Sincity Press 2025. All rights are reserved